JPWO2022197763A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022197763A5 JPWO2022197763A5 JP2023557369A JP2023557369A JPWO2022197763A5 JP WO2022197763 A5 JPWO2022197763 A5 JP WO2022197763A5 JP 2023557369 A JP2023557369 A JP 2023557369A JP 2023557369 A JP2023557369 A JP 2023557369A JP WO2022197763 A5 JPWO2022197763 A5 JP WO2022197763A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- independently selected
- sulfur
- nitrogen
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 42
- 150000001875 compounds Chemical class 0.000 claims 37
- 229910052757 nitrogen Inorganic materials 0.000 claims 22
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 21
- 125000005842 heteroatom Chemical group 0.000 claims 21
- 229910052760 oxygen Inorganic materials 0.000 claims 21
- 239000001301 oxygen Substances 0.000 claims 21
- 229910052717 sulfur Chemical group 0.000 claims 21
- 239000011593 sulfur Chemical group 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 10
- 125000001931 aliphatic group Chemical group 0.000 claims 9
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000004980 cyclopropylene group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 1
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162487P | 2021-03-17 | 2021-03-17 | |
| US63/162,487 | 2021-03-17 | ||
| PCT/US2022/020491 WO2022197763A1 (en) | 2021-03-17 | 2022-03-16 | Inhibitors of plasma kallikrein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024512497A JP2024512497A (ja) | 2024-03-19 |
| JP2024512497A5 JP2024512497A5 (https=) | 2025-03-24 |
| JPWO2022197763A5 true JPWO2022197763A5 (https=) | 2025-03-24 |
Family
ID=81326196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557369A Pending JP2024512497A (ja) | 2021-03-17 | 2022-03-16 | 血漿カリクレインの阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240226106A1 (https=) |
| EP (1) | EP4308229A1 (https=) |
| JP (1) | JP2024512497A (https=) |
| CN (1) | CN117396469A (https=) |
| WO (1) | WO2022197763A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| CN114667289B (zh) | 2019-09-18 | 2025-08-26 | 武田药品工业有限公司 | 杂芳基血浆激肽释放酶抑制剂 |
| EP4031547B1 (en) | 2019-09-18 | 2024-07-17 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| CA2385747A1 (en) * | 1999-09-17 | 2001-03-22 | Gavin C. Hirst | Pyrazolopyrimidines as therapeutic agents |
| IL156315A0 (en) * | 2000-12-07 | 2004-01-04 | Cv Therapeutics Inc | Abca-1 elevating compounds |
| AR077033A1 (es) * | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
| WO2014074715A1 (en) * | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| CN105849097A (zh) * | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | 取代的吡啶衍生物用作gsk-3抑制剂 |
| WO2015164308A1 (en) * | 2014-04-22 | 2015-10-29 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| AU2016247768B2 (en) * | 2015-04-17 | 2019-03-07 | Corteva Agriscience Llc | Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto |
| US10287288B2 (en) * | 2015-07-29 | 2019-05-14 | Bristol-Myers Squibb | Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties |
| RU2019133646A (ru) * | 2017-03-30 | 2021-04-30 | Ф. Хоффманн-Ля Рош Аг | Изохинолины в качестве ингибиторов hpk1 |
| MX2019011511A (es) * | 2017-03-30 | 2019-11-18 | Hoffmann La Roche | Naftiridinas como inhibidores de cinasa 1 progenitora hematopoyetica (hpk1). |
| MX2020005210A (es) * | 2017-11-21 | 2020-08-20 | Bristol Myers Squibb Co | Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona. |
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| TW202116753A (zh) * | 2019-07-11 | 2021-05-01 | 大陸商南京征祥醫藥有限公司 | 以噌啉作為hpk1的抑制劑 |
| CN114516867B (zh) * | 2020-04-28 | 2023-09-15 | 江南大学 | 一类含氧五元杂环化合物、合成方法、药物组合物及用途 |
-
2022
- 2022-03-16 US US18/550,504 patent/US20240226106A1/en active Pending
- 2022-03-16 CN CN202280033915.5A patent/CN117396469A/zh active Pending
- 2022-03-16 EP EP22714697.4A patent/EP4308229A1/en active Pending
- 2022-03-16 WO PCT/US2022/020491 patent/WO2022197763A1/en not_active Ceased
- 2022-03-16 JP JP2023557369A patent/JP2024512497A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI849082B (zh) | 蛋白酪胺酸磷酸酶抑制劑及其使用方法 | |
| JP2022141692A5 (https=) | ||
| RU2318816C2 (ru) | 4-замещенные имидазол-2-тионы и имидазол-2-оны в качестве агонистов альфа2b- и альфа2c- адренергических рецепторов | |
| JP2020525442A5 (https=) | ||
| JP5330324B2 (ja) | Ｆｐアゴニストとして有用な、芳香族のあるｃ１６〜ｃ２０が置換されたテトラヒドロプロスタグランジン類 | |
| JP5265518B2 (ja) | アルテミシニン誘導体の二量体、この調製およびこの治療上の使用 | |
| JP2016513112A5 (https=) | ||
| JP2018536634A5 (https=) | ||
| HUE034869T2 (en) | Combination therapy with substituted oxazolidinones | |
| JP2019524883A5 (https=) | ||
| JP2009526761A5 (https=) | ||
| KR20170139122A (ko) | Ｒｓｖ 항바이러스 피라졸로- 및 트리아졸로-피리미딘 화합물 | |
| JP2015508408A (ja) | プロスタグランジン類似体の結晶型およびその製造方法と用途 | |
| JP2011527704A (ja) | 経口抗がん製剤 | |
| EP1095043A1 (en) | Trioxane derivatives | |
| WO2015151490A1 (ja) | 新規な三環性キノン誘導体 | |
| EA020885B1 (ru) | Ингибиторы протеинкиназы и их применение | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| WO2011050284A1 (en) | Pyrazolylpyridine antiviral agents | |
| AU2015287334A1 (en) | Isoindoline derivatives for use in the treatment of a viral infection | |
| EP4337203A1 (en) | Inhibitors of the menin-mll interaction | |
| JP2021512125A5 (https=) | ||
| JPWO2019236890A5 (https=) | ||
| JP2021512132A (ja) | 置換イミダゾールカルボン酸エステル系誘導体およびその使用 | |
| JPWO2021055621A5 (https=) |